Results 11 to 20 of about 111,761,865 (181)

Determination of Anti-Phospholipase A2 and Anti-Thrombospondin Type 1 Domain-Containing Protein 7A in Latin Patients with Membranous Nephropathy

Diagnostics, 2022
Primary membranous nephropathy (MN) is caused by antibodies against podocyte antigens, especially the type M receptor of phospholipase A2 (PLA2R) and thrombospondin type-1 domain containing 7 A (THSD7A).
Ligia C. Battaini, Otavio T. Ranzani, Lia J. Marçal, Leila Antonangelo, Lecticia B. Jorge, Cristiane D. Bitencourt, Victoria Woronik, Denise M. A. Malheiros, Luis Yu   +8 more
doaj   +4 more sources

Thrombospondin Type 1 Domain-Containing 7A (THSD7A)-Associated Membranous Nephropathy Leading to Metastatic Neuroendocrine Carcinoma. [PDF]

Cureus, 2023
Idiopathic membranous nephropathy also known as primary membranous nephropathy (PMN) is a common cause of nephrotic syndrome often seen in nondiabetic adults worldwide, rising as high as 40% in adults over the age of 60. Most PMN is mediated by antibodies to the M-type phospholipase A2 receptor (anti-PLA2R) in nearly 70%-80% of individuals ...
Juarez A, Galindo L, Ragunathan A, Gondal M.   +3 more
europepmc   +5 more sources

Human anti-thrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway. [PDF]

Biosci Rep, 2018
To investigate whether the human anti-thrombospondin type 1 domain-containing 7A (THSD7A) antibody-induced membranous nephropathy (MN) is mediated by activating lectin complement pathway. Automatic biochemical apparatus was used to assess renal function of mice. The serum levels of anti-THSD7A antibodies and complement were tested by using ELISA.
Wang Z, Wen L, Dou Y, Zhao Z.
europepmc   +4 more sources

Clinical significance of the determination of antibodies to thrombospondin type 1 containing domain 7A (THSD7A) in membranous nephropathy

Терапевтический архив, 2023
Background. Membranous nephropathy (MN) is an immunocomplex glomerular disease, which is the most common cause of nephrotic syndrome in adults. Numerous studies have established that autoantibodies against the target podocyte autoantigens, including the ...
Patimat A. Kakhsurueva, Elena S. Kamyshova, Irina N. Bobkova, Ekaterina V. Stavrovskaya, Tatiana E. Rudenko, Elena Y. Andreeva   +5 more
doaj   +3 more sources

Correlation Between THSD7A Expression and Tumor Characteristics of Azoxymethane-Induced Colon Cancer Model in Rats

The Turkish Journal of Gastroenterology, 2021
Background: Thrombospondin type 1 domain-containing 7A (THSD7A) has emerged as a new potential molecular tool for multiple tumors since that THSD7A was detected to be expressed in various malignant tumor types including colorectal cancer (CRC).
Oktay Halit Aktepe, Taha Koray Sahin, Gurkan Guner, Deniz Can Guven, Haci Hasan Yeter, Olcay Kurtulan, Ibrahim Hanifi Ozercan, Omer Dizdar, Suayib Yalcin   +8 more
doaj   +2 more sources

Systemic sclerosis complicated with membranous nephropathy positive for type 1 thrombospondin-7A domain:one case report with a literature review

Linchuang shenzangbing zazhi, 2021
系统性硬化症（systemic sclerosis,SSc）是一种以皮肤炎症、变性、增厚和纤维化进而硬化和萎缩为特征,同时伴有内脏器官受累的结缔组织病,可累及肺、肾脏、消化道、心脏等内脏器官。肾脏受累表现为肾病综合征（nephrotic syndrome,NS）的SSc国内外罕见,而肾脏病理检查结果为肾小球1型血小板反应蛋白7A域（thrombospondin type 1 domain-containing 7A,THSD7A）
Xue Hen, Huang Qiu-ping, Ma Xia
doaj   +1 more source

Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy [PDF]

Kidney International, 2019
Autoantibodies against phospholipase A2 receptor 1 (PLA2R1) and thrombospondin type 1 domain-containing 7A (THSD7A) are emerging as biomarkers to classify membranous nephropathy (MN) and to predict outcome or response to treatment. Anti-THSD7A autoantibodies are detected by Western blot and indirect immunofluorescence test (IIFT).
Zaghrini, Christelle, Seitz-Polski, Barbara, Justino, Joana, Dolla, Guillaume, Payre, Christine, Jourde-Chiche, Noemie, van de Logt, Anne-Els, Booth, Caroline, Rigby, Emma, Lonnbro-Widgren, Jennie, Nystrom, Jenny, Mariat, Christophe, Cui, Zhao, Wetzels, Jack F.M., Ghiggeri, Gianmarco, Beck, Laurence, Ronco, Pierre, Debiec, Hanna, Lambeau, Gérard   +18 more
openaire   +6 more sources

Critical evaluation of cancer risks in glomerular disease

Translational Oncology, 2022
The increased cancer incidence in patients with glomerular disease can be secondary to an intrinsic immune dysfunction associated with the disease or/and extrinsic factors, especially immunosuppressants. The treatment for paraneoplastic glomerulopathy is
Zaw Thet, Alfred K. Lam, Dwarakanathan Ranganathan, Soe Yu Aung, Thin Han, Tien K. Khoo   +5 more
doaj   +2 more sources

Genetic determinants of the development and course of membranous nephropathy [PDF]

Терапевтический архив, 2018
Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in adults and is classified as either primary (idiopatic) or secondary MN according to underlying etiology (the later result from some known disease such as systemic ...
E S Kamyshova, I N Bobkova, I A Gorelova, P A Kakhsurueva, E E Filatova   +4 more
doaj   +3 more sources

Routine immunohistochemical staining in membranous nephropathy: in situ detection of phospholipase A2 receptor and thrombospondin type 1 containing 7A domain

Journal of Nephrology, 2018
Membranous nephropathy (MN) can be idiopathic (iMN) or manifest as a result of systemic underlying conditions as a secondary epiphenomenon. For the prognostic and predictive consequences of this discrimination, the routine use of reliable markers is crucial.
L'Imperio, V, Pieruzzi, F, Sinico, RA, Nebuloni, M, Granata, A, Smith, A, Radice, A, Pagni, F   +7 more
openaire   +4 more sources